AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
AAC Accepts, published online ahead of print on 26 March 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01028-06v1
51/6/1934    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McVay, C. S.
Right arrow Articles by Fralick, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McVay, C. S.
Right arrow Articles by Fralick, J. A.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01028-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Phage therapy of Pseudomonas aeruginosa infection in the burn mouse model

Catherine S. McVay, Marisela Velásquez, and Joe A. Fralick*

* To whom correspondence should be addressed. Email: joe.fralick{at}ttmc.ttuhsc.edu.


   Abstract

Mice, compromised by a burn wound injury and subjected to a fatal infection of Pseudomonas aeruginosa, were administered a single dose of a Pseudomonas aeruginosa (Pa) phage cocktail, consisting of three different Pa phages, via three different routes: intramuscularly (IM), subcutaneously (SC), or intraperitoneally (IP). The results of these studies indicated that a single dose of the Pa phage cocktail could significantly decrease the mortality of thermally injured, P. aeruginosa infected mice (from 6% survival without treatment to 22-87% survival with treatment) and that the route of administration was particularly important to the efficacy of the treatment, with the IP route providing the most significant (87%) protection. Pharmacokinetics of phage delivery to the blood, spleen and liver suggested that phage administered by the IP route were delivered at a higher dose, earlier and for a more sustained period of time than were those administered via IM or SC which may explain the differences in efficacy via these three different routes of administration.







Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.